German giant Boehringer Ingelheim has disclosed negative top-line results from the Phase III CONNEX study for its iclepertin, a treatment for cognitive impairment in adults with schizophrenia. The study failed to meet either primary or key secondary endpoints, indicating no statistically significant effects on cognition or functioning in patients treated with iclepertin versus placebo at six months. Despite this, the glycine transporter 1 (GlyT1) inhibitor was well tolerated, with safety profiles aligning with previous findings.
Iclepertin: Drug Profile and Mechanism of Action
Iclepertin (BI 425809) is a best-in-class therapy for cognitive impairment associated with schizophrenia (CIAS). It is designed to improve the functional impairment of N-methyl-D-aspartate (NMDA) receptors by inhibiting GlyT1, thereby exerting its therapeutic effect. The Phase III CONNEX study aimed to evaluate the efficacy and safety of iclepertin in this patient population.
Study Outcomes and Implications
The results of the CONNEX study are disappointing, as they indicate that iclepertin did not demonstrate the expected benefits in improving cognitive function or overall functioning in patients with schizophrenia. This outcome highlights the challenges in developing effective treatments for cognitive impairment in this complex psychiatric disorder. Despite the negative results, the safety and tolerability of iclepertin remain promising, suggesting that further research may be warranted to explore its potential in other indications or patient populations.
Strategic Implications
The failure to meet the endpoints in the Phase III CONNEX study is a significant setback for Boehringer Ingelheim’s development program for iclepertin. It underscores the complexity of treating cognitive impairment in schizophrenia and the need for continued innovation and research in this area. The company will likely need to reevaluate its strategy for iclepertin and consider alternative approaches to address the unmet needs of patients with CIAS.-Fineline Info & Tech
Leave a Reply